Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Risk factors for asymptomatic diverticulosis

ABSTRACT: Risk factors for asymptomatic diverticulosis

PROVIDER: PRJNA1077097 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of stroke-susceptible and asymptomatic human carotid plaques

Project description:A microarray analysis of advanced human atherosclerotic carotid artery plaques (equal or over 70% stenosis, NASCET criteria) from radiologically confirmed ipsilateral stroke patients (stroke-susceptible plaques, n=12) compared with carotid plaques collected from clinically asymptomatic patients with clear brain imaging (asymptomatic plaques, n=9) with equivalent conventional risk factors and severity of carotid stenosis.

2011-12-30 | E-MEXP-2257 | biostudies-arrayexpress

NEI:Myopia and Glaucoma Risk Factors at CIDR

Project description:NEI:Myopia and Glaucoma Risk Factors at CIDR

| PRJNA75493 | ENA

Genetic and Trauma-Related Risk factors for PTSD

Project description:Genetic and Trauma-Related Risk factors for PTSD

| PRJNA637793 | ENA

Genetic and Trauma-Related Risk factors for PTSD

Project description:Genetic and Trauma-Related Risk factors for PTSD

| PRJNA637794 | ENA

Ovarian Tumor Risk and Environmental and Genetic Factors

Project description:Ovarian Tumor Risk and Environmental and Genetic Factors

| PRJNA302695 | ENA

Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malaria

Project description:To define the impact of asymptomatic malaria, we pursued a systems approach integrating antibody responses, mass cytometry, and transcriptional profiling of individuals experiencing symptomatic and asymptomatic P. falciparum infection. Defined populations of classical and atypical memory B cells and a TH2 cell bias were associated with reduced risk of clinical malaria. Despite these protective responses, asymptomatic malaria featured an immunosuppressive transcriptional signature with upregulation of pathways involved in the inhibition of T cell function, and CTLA-4 as a predicted regulator in these processes.

2022-02-21 | GSE181179 | GEO

Genetic and Environmental Risk Factors for Hemorrhagic Stroke study

Project description:Genetic and Environmental Risk Factors for Hemorrhagic Stroke study

| PRJNA276717 | ENA

Genetic and Environmental Risk Factors for Cocaine Addiction (COCCAINE)

Project description:Genetic and Environmental Risk Factors for Cocaine Addiction (COCCAINE)

| PRJNA532956 | ENA

Genetic and Environmental Risk Factors for Cocaine Addiction (COCCAINE)

Project description:Genetic and Environmental Risk Factors for Cocaine Addiction (COCCAINE)

| PRJNA532957 | ENA

Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2

Project description:The immune responses and mechanisms limiting symptom progression in asymptomatic cases of SARS-CoV-2 infection remain unclear. We comprehensively characterized transcriptomic profiles, cytokine responses, neutralization capacity of antibodies and cellular immune phenotypes of asymptomatic patients with acute SARS-CoV-2 infection to identify potential protective mechanisms. Compared to symptomatic patients, asymptomatic patients had higher counts of mature neutrophils and lower proportion of CD169+ expressing monocytes in the peripheral blood. Systemic levels of pro-inflammatory cytokines were also lower in asymptomatic patients, accompanied by milder pro-inflammatory gene signatures. Mechanistically, a more robust systemic Th2 cell signature with a higher level of virus-specific Th17 cells and a weaker yet sufficient neutralizing antibody profile against SARS-CoV-2 was observed in asymptomatic patients. In addition, asymptomatic COVID-19 patients had higher systemic levels of growth factors that are associated with cellular repair. Together, asymptomatic patients mount less pro-inflammatory and more protective immune responses against SARS-CoV-2 indicative of disease tolerance. Insights from this study highlight key immune pathways that could serve as therapeutic targets to prevent disease progression in COVID-19.

2021-04-24 | GSE166424 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data